ficonalkib

Ficonalkib is an orally bioavailable, third-generation inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). It is designed to treat ALK-positive non-small cell lung cancer (NSCLC), particularly in patients who have developed resistance to first- and second-generation ALK inhibitors. Ficonalkib demonstrates high selectivity for ALK, potent activity against a range of ALK mutations—including those that confer resistance to earlier therapies—and strong central nervous system (CNS) penetration. Early-phase clinical trials indicate that ficonalkib has systemic and intracranial efficacy comparable to lorlatinib, another third-generation ALK inhibitor, but may offer a more favorable toxicity profile. The drug is being developed primarily for use in patients with advanced or metastatic ALK-positive NSCLC who have failed prior lines of therapy.

Brand names

Ficonalkib

Other names

ficonalkibLTK tyrosine kinase inhibitor - Shouyao Holdings